{"nctId":"NCT01371721","briefTitle":"A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD","startDateStruct":{"date":"2012-02"},"conditions":["Major Depressive Disorder"],"count":269,"armGroups":[{"label":"Desvenlafaxine Succinate Sustained-Release","type":"EXPERIMENTAL","interventionNames":["Drug: DVS SR"]}],"interventions":[{"name":"DVS SR","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Completed study B2061014 and who in the investigator's opinion would benefit from long term treatment with DVS SR\n* Willingness and ability to comply with scheduled visits, treatment plan and procedures\n\nExclusion Criteria:\n\n* Subject requires precaution against suicide\n* Subject not in a generally healthy condition","healthyVolunteers":false,"sex":"ALL","minimumAge":"7 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Change From Baseline at Week 26 in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score Based on Observed Cases","description":"Clinician-rated interview-based scale (with both child and parent or guardian) to assess 17 distinct symptom areas to derive an index of depression severity. Discrepancies between informants' responses were resolved by using most impaired rating given by valid informant. Rated on a 7-point scale; range from 1 (no impairment) to 7 (indicates greater impairment). Total score calculated as sum of the 17 items (range 1 to 119); higher score indicates greater impairment. Adjusted mean presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.55","spread":"10.80"},{"groupId":"OG001","value":"-6.41","spread":"11.50"},{"groupId":"OG002","value":"-5.32","spread":"7.29"},{"groupId":"OG003","value":"-5.78","spread":"10.03"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at Week 26 in the Clinical Global Impression of Severity (CGI-S) Score Based on Observed Cases","description":"A 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected. Change: score at observation minus score at baseline. Adjusted mean presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.78","spread":"1.23"},{"groupId":"OG001","value":"-0.77","spread":"1.16"},{"groupId":"OG002","value":"-0.82","spread":"0.92"},{"groupId":"OG003","value":"-0.79","spread":"1.10"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Clinical Global Impression, Improvement (CGI-I) Response Defined as a Score of 'Very Much Improved' or 'Much Improved' at Week 26","description":"A 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Higher score = more affected.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","spread":null},{"groupId":"OG001","value":"93.4","spread":null},{"groupId":"OG002","value":"92.9","spread":null},{"groupId":"OG003","value":"92.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Remission as Determined by a CDRS-R Score of â‰¤28 at Week 26 Based on Observed Cases","description":"Clinician-rated interview-based scale (with both child and parent or guardian) to assess 17 distinct symptom areas to derive an index of depression severity. Discrepancies between informants' responses were resolved by using most impaired rating given by valid informant. Rated on a 7-point scale; range from 1 (no impairment) to 7 (indicates greater impairment). Total score calculated as sum of the 17 items (range 1 to 119); higher score indicates greater impairment. Adjusted mean presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.5","spread":null},{"groupId":"OG001","value":"78.7","spread":null},{"groupId":"OG002","value":"73.2","spread":null},{"groupId":"OG003","value":"75.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Experiencing a Treatment Emergent Adverse Event","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.1","spread":null},{"groupId":"OG001","value":"75.3","spread":null},{"groupId":"OG002","value":"73.9","spread":null},{"groupId":"OG003","value":"73.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants by Clinical Global Impression Improvement (CGI-I) Score at Week 26 Based on Observed Cases","description":"A 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.6","spread":null},{"groupId":"OG001","value":"63.9","spread":null},{"groupId":"OG002","value":"57.1","spread":null},{"groupId":"OG003","value":"61.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.3","spread":null},{"groupId":"OG001","value":"29.5","spread":null},{"groupId":"OG002","value":"35.7","spread":null},{"groupId":"OG003","value":"30.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null},{"groupId":"OG001","value":"3.3","spread":null},{"groupId":"OG002","value":"5.4","spread":null},{"groupId":"OG003","value":"4.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null},{"groupId":"OG001","value":"1.6","spread":null},{"groupId":"OG002","value":"1.8","spread":null},{"groupId":"OG003","value":"2.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"1.6","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":87},"commonTop":["Headache","Nausea","Weight increased","Upper respiratory tract infection","Abdominal pain upper"]}}}